Private company

Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Inc. is a pharmaceutical preparations company.1 It is headquartered in Wakefield, Massachusetts.1

Last updated Oct 20, 2026.

Overview

$0Revenue, fiscal 20232
-$3.2MNet income, fiscal 20232
  • IndustryPharmaceutical Preparations1
  • HeadquartersWakefield, Massachusetts1
  • Business address301 Edgewater Place, Suite 100, Wakefield, Ma 018803
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-100.0%Revenue growth, 20232
-155.4%Return on equity2

Financial statements

Revenue4562$0 in 2023
0$200.0K$400.0K$600.0K2019: $0$020192020: $423.0K$423.0K20202021: $0$020212022: $18.0K$18.0K20222023: $0$02023
Operating income789562-$3.1M in 2023−75% since 2016
-$20.0M-$15.0M-$10.0M-$5.0M02016: -$12.7M-$12.7M20162017: -$15.3M-$15.3M2017+21%2018: -$13.9M-$13.9M2018−9%2019: -$6.5M-$6.5M2019−54%2020: -$4.6M-$4.6M2020−28%2021: -$9.0M-$9.0M2021+94%2022: -$6.9M-$6.9M2022−23%2023: -$3.1M-$3.1M2023−55%
Net income7894562-$3.2M in 2023−75% since 2016
-$20.0M-$15.0M-$10.0M-$5.0M02016: -$12.9M-$12.9M20162017: -$15.5M-$15.5M2017+21%2018: -$16.4M-$16.4M2018+5%2019: -$8.7M-$8.7M2019−47%2020: -$6.6M-$6.6M2020−23%2021: -$13.9M-$13.9M2021+109%2022: -$7.0M-$7.0M2022−49%2023: -$3.2M-$3.2M2023−55%
Fiscal year20162017201820192020202120222023
Revenue$04$423.0K5$06$18.0K2$02
Research and development$9.0M7$12.8M8$11.4M9$4.3M4$2.8M5$7.0M6$4.8M2$1.5M2
Operating expenses$6.9M2$2.9M2
Operating income-$12.7M7-$15.3M8-$13.9M9-$6.5M9-$4.6M5-$9.0M6-$6.9M2-$3.1M2
Interest$202.0K7$202.0K8$202.0K8$2.0M4$52.0K4
Income tax$04$05$06$02$02
Net income-$12.9M7-$15.5M8-$16.4M9-$8.7M4-$6.6M5-$13.9M6-$7.0M2-$3.2M2
Earnings per share-$0.117-$0.127
Earnings per share (diluted)-$0.117-$0.127

Compare Innovation Pharmaceuticals Inc. with another company

Corporate structure

Innovation Pharmaceuticals Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Innovation Pharmaceuticals Inc.

  • Kips Bay Select LP Filed SC 13G/A on Innovation Pharmaceuticals Inc., latest Jul 5, 2022
  • Innovation Pharmaceuticals Inc. Wakefield, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Innovation Pharmaceuticals Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.5M2 Jun 30, 2023$3.8M2 Jun 30, 2022−60.1%
Stakes in other companies (equity method)$3.8M2 Jun 30, 2023$4.0M2 Jun 30, 2022−4.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization-$3.4M2 Jun 30, 2023-$3.1M2 Jun 30, 2022−12.2%
Finite-lived intangibles, net$2.0M2 Jun 30, 2023$2.3M2 Jun 30, 2022−13.5%
Patents, net$5.4M2 Jun 30, 2023$5.4M2 Jun 30, 2022+1.1%

Leadership

Who has led Innovation Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Leo Ehrlich2012–2023

Chair

  1. Leo Ehrlich2019–2023

President

  1. Krishna Menon2008–2015
  2. Arthur Peter Bertolino2017–2019

Chief financial officer

  1. Leo Ehrlich2008
2010201520202025
Board members and other officers (8)

Former names

  • Cellceutix CORPSep 24, 2008 to May 9, 20173
  • EconoShare, Inc.Jul 14, 2006 to May 15, 20083

Timeline

  1. Feb 1, 20248-K Executive or director change; Other events25
  2. Dec 5, 20238-K Ended a material agreement26
  3. Oct 30, 20238-K Change of auditor27
  4. Jan 4, 20238-K Other events28
  5. Jun 15, 20228-K Entered a material agreement; Regulation FD disclosure29
  6. Oct 14, 20218-K Executive or director change30
  7. Jul 30, 2012New chief executive Leo Ehrlich becomes CEO14

Filings

23 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 6 major events, 5 insider forms, 1 large holders, 2 other. The latest 20:

  1. Feb 1, 20248-K EDGAR
  2. Dec 5, 20238-K EDGAR
  3. Nov 20, 202310-Q EDGAR
  4. Nov 15, 2023NT 10-Q EDGAR
  5. Oct 30, 20238-K EDGAR
  6. Sep 28, 202310-K EDGAR
  7. May 15, 202310-Q EDGAR
  8. Feb 15, 202310-Q EDGAR
  9. Feb 15, 2023NT 10-Q EDGAR
  10. Jan 4, 20238-K EDGAR
  11. Jan 4, 20234 EDGAR
  12. Nov 10, 202210-Q EDGAR
  13. Sep 28, 202210-K EDGAR
  14. Sep 28, 20224 EDGAR
  15. Sep 28, 20224 EDGAR
  16. Sep 28, 20224 EDGAR
  17. Sep 28, 20224 EDGAR
  18. Jul 5, 2022SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G EDGAR
  19. Jun 15, 20228-K EDGAR
  20. May 13, 202210-Q EDGAR

The 23 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Innovation Pharmaceuticals Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInnovation Pharmaceuticals Inc.1
  • CIK0001355250
  • Employer ID (EIN)30-05656451
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address301 Edgewater Place, Suite 100, Wakefield, MA 018801
  • Phone978-921-41251
  • Shares outstanding514,013,755 as of Sep 10, 20232
  • Public float$9.2M as of Dec 31, 20222
  • On EDGAR sinceJul 14, 20061
  • Filings304 in all: 8-K (89), 10-Q (47), 4 (26), 10-K (15), UPLOAD (14), NT 10-Q (12), SC 13G/A (9), 3 (8)1
    All 40 form types

    424B5 (8), CORRESP (8), EFFECT (7), 10QSB (5), NT 10-K (5), S-3 (5), 10-K/A (4), 424B3 (4), 5 (3), PRER14C (3), SC 13G (3), 10KSB (2), 10QSB/A (2), 8-K/A (2), D (2), DEF 14A (2), DEF 14C (2), POS AM (2), S-8 (2), 10-Q/A (1), 3/A (1), 424B2 (1), 8-A12B (1), 8-A12G (1), D/A (1), DEFA14A (1), PRE 14A (1), PRE 14C (1), PREM14C (1), REGDEX (1), S-3/A (1), SB-2 (1)

  • Latest filingsAnnual report (10-K) Sep 28, 2023
    Quarterly report (10-Q) Nov 20, 2023
    Proxy statement (DEF 14A) Aug 13, 2019
    Latest 8-K (8-K) Feb 1, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31